新的药物抗逆转录病毒药物对患有ESR1突变的晚期乳腺癌患者有重大益处。 New drug vepdegestrant shows significant benefit for advanced breast cancer patients with ESR1 mutations.

Pfizer和Arvinas研制的一种实验性药物Vepdegestrant在治疗患有ESR1基因突变的晚期乳腺癌患者方面显示了希望。 An experimental drug, vepdegestrant, developed by Pfizer and Arvinas, shows promise in treating advanced breast cancer patients with ESR1 gene mutations. 与AstraZeneca的Faslodex的Faslodex大约两个月相比,在第三阶段的试验中,它将无病期延长了五个月,而在这一特殊突变的病人中,AstraZeneca的Faslodex大约延长了两个月。 In a phase 3 trial, it extended the period without disease progression by five months compared to approximately two months for AstraZeneca’s Faslodex, in patients with this specific mutation. 该药物属于一个新的类别 瞄准并打破蛋白质 驱动肿瘤生长。 The drug belongs to a new class that targets and breaks down proteins driving tumor growth. 虽然在总体患者群体中受益有限,但对于那些有ESR1突变的人来说,这可能是一个重大进步。 While it showed limited benefit in the overall patient group, it could be a significant advancement for those with ESR1 mutations.